Pearl Pathways has hired Nancy Kant as clinical services advisor to support biopharmaceutical and diagnostic life science companies. A skilled biologist, she has more than 35 years of experience in the pharmaceutical and diagnostics industries and academic basic research. Kant’s expertise includes evaluating and implementing new technologies, developing novel clinical and research laboratory methods and bioassays, biochemical reagent manufacture testing, and coordinating external partnerships. Her scientific experience spans a variety of medical disciplines including medical imaging, neuroscience, pathology, immunology, cancer biology and orthopedics.
Kant’s career includes 16 years at Eli Lilly and Co., 12 years at Roche Diagnostics Corp. (formerly Boehringer Mannheim Corp.), and eight years in academia. Most recently, she served as a technical process expert at Eli Lilly and was responsible for the operational and quality management of PET tracer development programs which translated novel radiotracers from preclinical testing through clinical validation. This included clinical trial oversight of academic PET centers and assessment of CGMP PET tracer manufacturing and sterile dispensing operations within the evolving scope of USP and FDA regulatory requirements.
As Clinical Services Advisor, Kant coordinates and manages clinical research activities for Pearl Pathways’ clients, ensuring studies are conducted in accordance with the protocol, relevant SOPs, and good clinical practices. Kant also provides medical writing, CRO, and CRC support services in addition to coordinating IRB submission activities at the site or study level.